Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005, 149(2):225-236 | DOI: 10.5507/bp.2005.031

MATRIX METALLOPROTEINASES AND THEIR FUNCTION IN MYOCARDIUM

Jiří Kukačkaa,b, Richard Průšaa, Karel Kotaškaa, Václav Pelouchb
a Department of Clinical Biochemistry and Pathobiochemistry Faculty Hospital Motol and 2nd Medical Faculty of Charles University
b Department of Medical Chemistry and Biochemistry of Charles University, 2nd Medical Faculty, Prague, Czech Republic

A significant number of myocardial diseases are accompanied by increased synthesis and degradation of the extracellular matrix (ECM) as well as by changed maturation and incorporation of ECM components. Important groups of enzymes responsible for both normal and pathological processes in ECM remodeling are matrix metaloproteinases (MMPs). These enzymes share a relatively conserved structure with a number of identifiable modules linked to their specific functions. The most important function of MMPs is the ability to cleave various ECM components; including such rigid molecules as fibrillar collagen molecules. The amount and activity of MMPs in cardiac tissue are regulated by a range of activating and inhibiting processes. Although MMPs play multifarious roles in many myocardial diseases, here we have focused on their function in ischemic cardiac tissue, dilated cardiomyopathy and hypertrophied cardiac tissue. The inhibition of MMPs by means of synthetic inhibitors seems to be a promising strategy in cardiac disease treatment. Their effects on diseased cardiac tissue have been successfully tested in several experimental studies.

Keywords: Extracellular matrix, Matrix metalloproteinases (MMPs), Myocardium, Remodeling, MMP inhibitors

Received: June 10, 2005; Accepted: September 25, 2005; Published: December 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kukačka, J., Průša, R., Kotaška, K., & Pelouch, V. (2005). MATRIX METALLOPROTEINASES AND THEIR FUNCTION IN MYOCARDIUM. Biomedical papers149(2), 225-236. doi: 10.5507/bp.2005.031
Download citation

References

  1. Borkakoti N. (2000) Structural studies of matrix metalloproteinases. J Mol Med. 78, 261-268. Go to original source... Go to PubMed...
  2. Shapiro SD. (1998) Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol. 10, 602-608. Go to original source... Go to PubMed...
  3. Zagris N. (2001) Extracellular matrix in development of the early embryo. Micron. 32, 427-438. Go to original source... Go to PubMed...
  4. Birkedal-Hansen H. (1995) Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol. 7, 728-735. Go to original source... Go to PubMed...
  5. Arthur MJ. (2000) Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 279, G245-249. Go to original source... Go to PubMed...
  6. Brinckerhoff CE, Rutter JL, Benbow U. (2000) Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 6, 4823-4830.
  7. Obermuller N, Morente N, Kranzlin B, Gretz N, Witzgall R. (2001) A possible role for metalloproteinases in renal cyst development. Am J Physiol Renal Physiol. 280, F540-550. Go to original source... Go to PubMed...
  8. Stetler-Stevenson WG, Yu AE. (2001) Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol. 11, 143-152. Go to original source... Go to PubMed...
  9. Lee MH, Murphy G. (2004) Matrix metalloproteinases at a glance. J Cell Sci. 117, 4015-4016. Go to original source... Go to PubMed...
  10. Ala-aho R, Kahari VM. (2005) Collagenases in cancer. Biochimie. 87, 273-286. Go to original source... Go to PubMed...
  11. Overall CM, Lopez-Otin C. (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2, 657-672. Go to original source... Go to PubMed...
  12. Becker JW, Marcy AI, Rokosz LL, Axel MG, Burbaum JJ, Fitzgerald PM, Cameron PM, Esser CK, Hagmann WK, et al. (1995) Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci. 4, 1966-1976. Go to original source... Go to PubMed...
  13. Van Wart HE, Birkedal-Hansen H. (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A. 87, 5578-5582. Go to original source... Go to PubMed...
  14. Stocker W, Gomis-Ruth FX, Bode W, Zwilling R. (1993) Implications of the three-dimensional structure of astacin for the structure and function of the astacin family of zinc-endopeptidases. Eur J Biochem. 214, 215-231. Go to original source... Go to PubMed...
  15. Dhanaraj V, Ye QZ, Johnson LL, Hupe DJ, Ortwine DF, Dunbar JB, Jr., Rubin JR, Pavlovsky A, Humblet C, et al. (1996) X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure. 4, 375-386. Go to original source... Go to PubMed...
  16. Gomis-Ruth FX, Gohlke U, Betz M, Knauper V, Murphy G, Lopez-Otin C, Bode W. (1996) The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexinlike domain. J Mol Biol. 264, 556-566. Go to original source... Go to PubMed...
  17. Bode W. (1995) A helping hand for collagenases: the haemopexinlike domain. Structure. 3, 527-530. Go to original source... Go to PubMed...
  18. Buttner FH, Hughes CE, Margerie D, Lichte A, Tschesche H, Caterson B, Bartnik E. (1998) Membrane type 1 matrix metalloproteinase (MT1-MMP) cleaves the recombinant aggrecan substrate rAgg1mut at the aggrecanase and the MMP sites. Characterization of MT1-MMP catabolic activities on the interglobular domain of aggrecan. Biochem J. 333, 159-165. Go to original source... Go to PubMed...
  19. Nagase H, Woessner JF, Jr. (1999) Matrix metalloproteinases. J Biol Chem. 274, 21491-21494. Go to original source... Go to PubMed...
  20. Ye S. (2000) Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 19, 623-629. Go to original source... Go to PubMed...
  21. Murphy G, Nguyen Q, Cockett MI, Atkinson SJ, Allan JA, Knight CG, Willenbrock F, Docherty AJ. (1994) Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem. 269, 6632-6636. Go to original source...
  22. Uria JA, Lopez-Otin C. (2000) Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res. 60, 4745-4751. Go to PubMed...
  23. Wilson CL, Matrisian LM. (1996) Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol. 28, 123-136. Go to original source... Go to PubMed...
  24. Llano E, Pendas AM, Knauper V, Sorsa T, Salo T, Salido E, Murphy G, Simmer JP, Bartlett JD, et al. (1997) Identification and structural and functional characterization of human enamelysin (MMP- 20). Biochemistry. 36, 15101-15108. Go to original source... Go to PubMed...
  25. Lohi J, Wilson CL, Roby JD, Parks WC. (2001) Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem. 276, 10134-10144. Go to original source... Go to PubMed...
  26. Pendas AM, Knauper V, Puente XS, Llano E, Mattei MG, Apte S, Murphy G, Lopez-Otin C. (1997) Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem. 272, 4281-4286. Go to original source... Go to PubMed...
  27. Stracke JO, Hutton M, Stewart M, Pendas AM, Smith B, Lopez- Otin C, Murphy G, Knauper V. (2000) Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem. 275, 14809-14816. Go to original source... Go to PubMed...
  28. Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI, Strongin AY. (2001) Characterization of matrix metalloproteinase- 26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J. 356, 705-718. Go to original source... Go to PubMed...
  29. Pei D, Majmudar G, Weiss SJ. (1994) Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem. 269, 25849-25855. Go to original source...
  30. Ohnishi J, Ohnishi E, Jin M, Hirano W, Nakane D, Matsui H, Kimura A, Sawa H, Nakayama K, et al. (2001) Cloning and characterization of a rat ortholog of MMP-23 (matrix metalloproteinase- 23), a unique type of membrane-anchored matrix metalloproteinase and conditioned switching of its expression during the ovarian follicular development. Mol Endocrinol. 15, 747-764. Go to original source... Go to PubMed...
  31. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. (1997) Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J. 322, 809-814. Go to original source... Go to PubMed...
  32. Prockop DJ, Kivirikko KI. (1995) Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem. 64, 403- 434. Go to original source... Go to PubMed...
  33. Netzel-Arnett S, Fields GB, Birkedal-Hansen H, Van Wart HE, Fields G. (1991) Sequence specificities of human fibroblast and neutrophil collagenases. J Biol Chem. 266, 6747-6755. Go to original source...
  34. Aimes RT, Quigley JP. (1995) Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem. 270, 5872-5876. Go to original source... Go to PubMed...
  35. Allan JA, Hembry RM, Angal S, Reynolds JJ, Murphy G. (1991) Binding of latent and high Mr active forms of stromelysin to collagen is mediated by the C-terminal domain. J Cell Sci. 99, 789- 795. Go to original source... Go to PubMed...
  36. Murphy G, Allan JA, Willenbrock F, Cockett MI, OConnell JP, Docherty AJ. (1992) The role of the C-terminal domain in collagenase and stromelysin specificity. J Biol Chem. 267, 9612-9618. Go to original source...
  37. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. (1996) Biochemical characterization of human collagenase-3. J Biol Chem. 271, 1544-1550. Go to original source... Go to PubMed...
  38. De Souza SJ, Pereira HM, Jacchieri S, Brentani RR. (1996) Collagen/collagenase interaction: does the enzyme mimic the conformation of its own substrate? Faseb J. 10, 927-930. Go to original source... Go to PubMed...
  39. Chung L, Shimokawa K, Dinakarpandian D, Grams F, Fields GB, Nagase H. (2000) Identification of the (183)RWTNNFREY(191) region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity. J Biol Chem. 275, 29610- 29617. Go to original source... Go to PubMed...
  40. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. (1997) Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem. 272, 2446-2451. Go to original source... Go to PubMed...
  41. Wang Y, Johnson AR, Ye QZ, Dyer RD. (1999) Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain. J Biol Chem. 274, 33043- 33049. Go to original source... Go to PubMed...
  42. Ellerbroek SM, Wu YI, Stack MS. (2001) Type I collagen stabilization of matrix metalloproteinase-2. Arch Biochem Biophys. 390, 51-56. Go to original source... Go to PubMed...
  43. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG. (1991) Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem. 266, 7870-7875. Go to original source...
  44. Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, Senior RM, Werb Z. (2000) The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell. 102, 647-655. Go to original source... Go to PubMed...
  45. Kridel SJ, Chen E, Kotra LP, Howard EW, Mobashery S, Smith JW. (2001) Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem. 276, 20572-20578. Go to original source... Go to PubMed...
  46. Gronski TJ, Jr., Martin RL, Kobayashi DK, Walsh BC, Holman MC, Huber M, Van Wart HE, Shapiro SD. (1997) Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem. 272, 12189-12194. Go to original source... Go to PubMed...
  47. Stracke JO, Fosang AJ, Last K, Mercuri FA, Pendas AM, Llano E, Perris R, Di Cesare PE, Murphy G, et al. (2000) Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett. 478, 52-56. Go to original source... Go to PubMed...
  48. Auble DT, Brinckerhoff CE. (1991) The AP-1 sequence is necessary but not sufficient for phorbol induction of collagenase in fibroblasts. Biochemistry. 30, 4629-4635. Go to original source... Go to PubMed...
  49. Duivenvoorden WC, Hirte HW, Singh G. (1999) Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis. 17, 27-34. Go to original source... Go to PubMed...
  50. Wada K, Sato H, Kinoh H, Kajita M, Yamamoto H, Seiki M. (1998) Cloning of three Caenorhabditis elegans genes potentially encoding novel matrix metalloproteinases. Gene. 211, 57-62. Go to original source... Go to PubMed...
  51. Nagase H, Suzuki K, Morodomi T, Enghild JJ, Salvesen G. (1992) Activation mechanisms of the precursors of matrix metalloproteinases 1, 2 and 3. Matrix Suppl. 1, 237-244. Go to PubMed...
  52. Nagase H. (1998) Cell surface activation of progelatinase A (proMMP- 2) and cell migration. Cell Res. 8, 179-186. Go to original source... Go to PubMed...
  53. Spiegel S, Foster D, Kolesnick R. (1996) Signal transduction through lipid second messengers. Curr Opin Cell Biol. 8, 159- 167. Go to original source... Go to PubMed...
  54. Korzus E, Nagase H, Rydell R, Travis J. (1997) The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J Biol Chem. 272, 1188-1196. Go to original source... Go to PubMed...
  55. Fisher GJ, Datta SC, Talwar HS, Wang ZQ, Varani J, Kang S, Voorhees JJ. (1996) Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature. 379, 335-339. Go to original source... Go to PubMed...
  56. Brenneisen P, Wenk J, Klotz LO, Wlaschek M, Briviba K, Krieg T, Sies H, Scharffetter-Kochanek K. (1998) Central role of Ferrous/ Ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts. J Biol Chem. 273, 5279-5287. Go to original source... Go to PubMed...
  57. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K. (1995) The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 55, 434-439.
  58. Lim M, Martinez T, Jablons D, Cameron R, Guo H, Toole B, Li JD, Basbaum C. (1998) Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett. 441, 88-92. Go to original source... Go to PubMed...
  59. Li YY, McTiernan CF, Feldman AM. (2000) Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res. 46, 214-224. Go to original source... Go to PubMed...
  60. Xie B, Laouar A, Huberman E. (1998) Fibronectin-mediated cell adhesion is required for induction of 92-kDa type IV collagenase/ gelatinase (MMP-9) gene expression during macrophage differentiation. The signaling role of protein kinase C-beta. J Biol Chem. 273, 11576-11582. Go to original source... Go to PubMed...
  61. Seltzer JL, Lee AY, Akers KT, Sudbeck B, Southon EA, Wayner EA, Eisen AZ. (1994) Activation of 72-kDa type IV collagenase/ gelatinase by normal fibroblasts in collagen lattices is mediated by integrin receptors but is not related to lattice contraction. Exp Cell Res. 213, 365-374. Go to original source... Go to PubMed...
  62. Lijnen HR, Lupu F, Moons L, Carmeliet P, Goulding D, Collen D. (1999) Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. Thromb Haemost. 81, 799-807. Go to original source... Go to PubMed...
  63. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. (1992) Biochemical basis for multiple modes of activation of human fibroblast collagenase. Matrix Suppl. 1, 76-77. Go to PubMed...
  64. Nagase H. (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem. 378, 151-160.
  65. Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H. (1990) Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry. 29, 10261-10270. Go to original source... Go to PubMed...
  66. Suzuki K, Lees M, Newlands GF, Nagase H, Woolley DE. (1995) Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. Biochem J. 305, 301-306. Go to original source... Go to PubMed...
  67. Suzuki D, Miyazaki M, Jinde K, Koji T, Yagame M, Endoh M, Nomoto Y, Sakai H. (1997) In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int. 52, 111-119. Go to original source... Go to PubMed...
  68. Okada Y, Morodomi T, Enghild JJ, Suzuki K, Yasui A, Nakanishi I, Salvesen G, Nagase H. (1990) Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem. 194, 721-730. Go to original source... Go to PubMed...
  69. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 370, 61-65. Go to original source... Go to PubMed...
  70. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. (1995) Mechanism of cell surface activation of 72- kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 270, 5331-5338. Go to original source... Go to PubMed...
  71. Murphy G. (1995) Matrix metalloproteinases and their inhibitors. Acta Orthop Scand Suppl. 266, 55-60. Go to original source... Go to PubMed...
  72. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. (1990) Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a cysteine switch mechanism for activation. Proc Natl Acad Sci U S A. 87, 364-368. Go to original source... Go to PubMed...
  73. Kolkenbrock H, Orgel D, Hecker-Kia A, Noack W, Ulbrich N. (1991) The complex between a tissue inhibitor of metalloproteinases (TIMP-2) and 72-kDa progelatinase is a metalloproteinase inhibitor. Eur J Biochem. 198, 775-781. Go to original source... Go to PubMed...
  74. Kolkenbrock H, Hecker-Kia A, Orgel D, Ruppitsch W, Ulbrich N. (1994) Activity of ternary gelatinase A-TIMP-2-matrix metalloproteinase complexes. Biol Chem Hoppe Seyler. 375, 589-595. Go to original source... Go to PubMed...
  75. Ogata Y, Itoh Y, Nagase H. (1995) Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem. 270, 18506-18511. Go to original source... Go to PubMed...
  76. Ries C, Petrides PE. (1995) Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe Seyler. 376, 345-355. Go to PubMed...
  77. Fabunmi RP, Baker AH, Murray EJ, Booth RF, Newby AC. (1996) Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases- 1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J. 315, 335-342. Go to original source... Go to PubMed...
  78. Apte SS, Hayashi K, Seldin MF, Mattei MG, Hayashi M, Olsen BR. (1994) Gene encoding a novel murine tissue inhibitor of metalloproteinases (TIMP), TIMP-3, is expressed in developing mouse epithelia, cartilage, and muscle, and is located on mouse chromosome 10. Dev Dyn. 200, 177-197. Go to original source... Go to PubMed...
  79. Anand-Apte B, Bao L, Smith R, Iwata K, Olsen BR, Zetter B, Apte SS. (1996) A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol. 74, 853-862. Go to original source... Go to PubMed...
  80. Tummalapalli CM, Heath BJ, Tyagi SC. (2001) Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J Cell Biochem. 80, 512-521. Go to original source... Go to PubMed...
  81. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases- 1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 298, 29-32. Go to original source... Go to PubMed...
  82. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. (1994) Cell growth-promoting activity of tissue inhibitor of metalloproteinases- 2 (TIMP-2). J Cell Sci. 107, 2373-2379. Go to original source... Go to PubMed...
  83. Ponton A, Coulombe B, Skup D. (1991) Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res. 51, 2138-2143. Go to PubMed...
  84. Tyagi SC. (1997) Proteinases and myocardial extracellular matrix turnover. Mol Cell Biochem. 168, 1-12. Go to original source... Go to PubMed...
  85. Maisch B. (1996) Ventricular remodeling. Cardiology. 87, 2-10. Go to original source... Go to PubMed...
  86. Pelouch V, Jirmar R. (1993) Biochemical characteristics of cardiac collagen and its role in ventricular remodelling following infarction. Physiol Res. 42, 283-292.
  87. Schacherer C, Koops D, Wiemer J, Hartmann A, Weis M, Klepzig H, Zeiher AM, Olbrich HG. (1999) Extracellular matrix structure after heart transplantation. Int J Cardiol. 68, 115-120. Go to original source... Go to PubMed...
  88. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. (1994) Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol. 26, 279-292. Go to original source... Go to PubMed...
  89. Jones FS, Jones PL. (2000) The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn. 218, 235-259. Go to original source... Go to PubMed...
  90. Ross RS, Borg TK. (2001) Integrins and the myocardium. Circ Res. 88, 1112-1119. Go to original source... Go to PubMed...
  91. Cleutjens JP. (1996) The role of matrix metalloproteinases in heart disease. Cardiovasc Res. 32, 816-821. Go to original source... Go to PubMed...
  92. Tyagi SC, Kumar S, Voelker DJ, Reddy HK, Janicki JS, Curtis JJ. (1996) Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem. 63, 185-198. Go to original source... Go to PubMed...
  93. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. (1996) Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem. 155, 13-21. Go to original source... Go to PubMed...
  94. Tyagi SC, Matsubara L, Weber KT. (1993) Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin Biochem. 26, 191-198. Go to original source... Go to PubMed...
  95. Tyagi SC, Ratajska A, Weber KT. (1993) Myocardial matrix metalloproteinase(s): localization and activation. Mol Cell Biochem. 126, 49-59. Go to original source... Go to PubMed...
  96. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. (1995) Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 27, 1281-1292. Go to original source... Go to PubMed...
  97. Carlyle WC, Jacobson AW, Judd DL, Tian B, Chu C, Hauer KM, Hartman MM, McDonald KM. (1997) Delayed reperfusion alters matrix metalloproteinase activity and fibronectin mRNA expression in the infarct zone of the ligated rat heart. J Mol Cell Cardiol. 29, 2451-2463. Go to original source... Go to PubMed...
  98. Lindsey M, Wedin K, Brown MD, Keller C, Evans AJ, Smolen J, Burns AR, Rossen RD, Michael L, et al. (2001) Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation. 103, 2181-2187. Go to original source... Go to PubMed...
  99. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. (2000) Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation. 101, 1833- 1839. Go to original source... Go to PubMed...
  100. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, et al. (1999) Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 99, 3063-3070. Go to original source... Go to PubMed...
  101. Robert V, Besse S, Sabri A, Silvestre JS, Assayag P, Nguyen VT, Swynghedauw B, Delcayre C. (1997) Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest. 76, 729-738.
  102. Li YY, Feldman AM, Sun Y, McTiernan CF. (1998) Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation. 98, 1728-1734. Go to original source... Go to PubMed...
  103. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, 3rd, Spinale FG. (1998) Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 97, 1708-1715. Go to original source... Go to PubMed...
  104. Tyagi SC. (1998) Extracellular matrix dynamics in heart failure: a prospect for gene therapy. J Cell Biochem. 68, 403-410. Go to original source... Go to PubMed...
  105. Kukacka J, Bíbová J, Ruskoaho H, Pelouch V. (2002) Chronic hypoxia alters expression of extracellular matrix components in rat. Phys Res. 51, P21.
  106. Kukacka J, Bíbová J, Ruskoaho H, Pelouch V. (2002) The effect of hypoxia and hypercapnia on remodeling of extracellular matrix in rat heart. Faseb J. 16, A1116.
  107. Tyagi SC, Kumar SG, Haas SJ, Reddy HK, Voelker DJ, Hayden MR, Demmy TL, Schmaltz RA, Curtis JJ. (1996) Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardio myopathy. J Mol Cell Cardiol. 28, 1415-1428. Go to original source... Go to PubMed...
  108. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. (1998) Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res. 82, 482-495. Go to original source... Go to PubMed...
  109. Coker ML, Thomas CV, Clair MJ, Hendrick JW, Krombach RS, Galis ZS, Spinale FG. (1998) Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol. 274, H1516-1523. Go to original source... Go to PubMed...
  110. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF, Jr. (1996) Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol. 148, 1639-1648.
  111. Brower GL, Janicki JS. (2001) Contribution of ventricular remodeling to pathogenesis of heart failure in rats. Am J Physiol Heart Circ Physiol. 280, H674-683. Go to original source... Go to PubMed...
  112. Botos I, Scapozza L, Zhang D, Liotta LA, Meyer EF. (1996) Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci U S A. 93, 2749-2754. Go to original source... Go to PubMed...
  113. Whittaker M, Floyd CD, Brown P, Gearing AJ. (2001) Design and therapeutic application of matrix metalloproteinase inhibitors. (Chem. Rev. 1999, 99, 2735-2776. Published on the web september 8, 1999). Chem Rev. 101, 2205-2206. Go to original source... Go to PubMed...
  114. Xue CB, He X, Roderick J, DeGrado WF, Cherney RJ, Hardman KD, Nelson DJ, Copeland RA, Jaffee BD, et al. (1998) Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production. J Med Chem. 41, 1745-1748. Go to original source... Go to PubMed...
  115. Li YY, Kadokami T, Wang P, McTiernan CF, Feldman AM. (2002) MMP inhibition modulates TNF-[alpha] transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol. 282, H983-H989. Go to original source... Go to PubMed...
  116. Heath EI, Grochow LB. (2000) Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 59, 1043-1055. Go to original source... Go to PubMed...
  117. Heath EI, OReilly S, Humphrey R, Sundaresan P, Donehower RC, Sartorius S, Kennedy MJ, Armstrong DK, Carducci MA, et al. (2001) Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 48, 269-274. Go to original source... Go to PubMed...
  118. Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, Houck WV, Clair MJ, Kribbs SB, Johnson LL, et al. (1999) Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res. 85, 364-376. Go to original source... Go to PubMed...
  119. Wang W, Sawicki G, Schulz R. (2002) Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res. 53, 165-174. Go to original source... Go to PubMed...
  120. Peterson JT, Hallak H, Johnson L, Li H, OBrien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, et al. (2001) Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation. 103, 2303-2309. Go to original source... Go to PubMed...
  121. Li H, Simon H, Bocan TM, Peterson JT. (2000) MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res. 46, 298-306. Go to original source... Go to PubMed...
  122. Hidalgo M, Eckhardt SG. (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 93, 178-193. Go to original source... Go to PubMed...
  123. Golub LM, Ramamurthy N, McNamara TF, Gomes B, Wolff M, Casino A, Kapoor A, Zambon J, Ciancio S, et al. (1984) Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease. J Periodontal Res. 19, 651-655. Go to original source... Go to PubMed...
  124. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. (1998) Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 12, 12-26. Go to original source... Go to PubMed...
  125. Rodan GA, Fleisch HA. (1996) Bisphosphonates: mechanisms of action. J Clin Invest. 97, 2692-2696. Go to original source... Go to PubMed...
  126. Ichinose Y, Migita K, Nakashima T, Kawakami A, Aoyagi T, Eguchi K. (2000) Effects of bisphosphonate on the release of MMP-2 from cultured human osteoblasts. Tohoku J Exp Med. 192, 111-118. Go to original source... Go to PubMed...
  127. Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T. (1999) MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci. 878, 453-465. Go to original source... Go to PubMed...